Medication info
Dapflome Extended-Release Tablet 10/1000 mg (Dapagliflozin Propanediol Hydrate, Metformin Hydrochloride)

Dapflome Extended-Release Tablet 10/1000 mg (Dapagliflozin Propanediol Hydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Youngjin Pharmaceutical Co., Ltd.
Appearance
Yellow oval-shaped extended-release film-coated tablet with both sides convex
Packaging
30 tablets/box [(10 tablets/PTP (Alu-Alu) x 3)]
Approval status
Active

MFDS item code 202300429 · Approved 2023.01.31 · Insurance code 642405160

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This drug is generally administered once daily with the evening meal. The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior history of diabetes drug treatment who do not achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of diabetes drug treatment, the recommended starting dose of this drug is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this drug should provide the patient's current metformin dose or the nearest therapeutically appropriate dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this drug, this drug may be initiated at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this drug is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this drug have not been specifically evaluated in patients switching from other glucose-lowering drugs. Because changes may alter glycemic control, any change in treatment in patients with type 2 diabetes should be made under close monitoring. This drug should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this drug may be excreted in the stool as a soft, hydrated mass that resembles a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or greater and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this drug, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this drug is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this drug should be discontinued immediately. Renal function should be evaluated every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function is more likely to be decreased in elderly patients, this drug should be used with caution as age increases (see Precautions, 9. Administration to elderly patients).

Ingredients

Manufacturer
Youngjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar control issues
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used to improve blood sugar control in adults with type 2 diabetes along with diet and exercise therapy, through the combination of dapagliflozin and metformin. It can be used especially in cases where blood sugar control is insufficient, among patients with cardiovascular disease or risk factors. However, it is advisable to refer to additional information from a specialist regarding the risk of cardiovascular events. Overall, this medication aids in blood sugar control and cardiovascular health management for patients with type 2 diabetes.

How to take

Adult dose

The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This drug is generally administered once daily with the evening meal. The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior history of diabetes drug treatment who do not achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of diabetes drug treatment, the recommended starting dose of this drug is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this drug should provide the patient's current metformin dose or the nearest therapeutically appropriate dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this drug, this drug may be initiated at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this drug is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this drug have not been specifically evaluated in patients switching from other glucose-lowering drugs. Because changes may alter glycemic control, any change in treatment in patients with type 2 diabetes should be made under close monitoring. This drug should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this drug may be excreted in the stool as a soft, hydrated mass that resembles a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or greater and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this drug, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this drug is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this drug should be discontinued immediately. Renal function should be evaluated every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function is more likely to be decreased in elderly patients, this drug should be used with caution as age increases (see Precautions, 9. Administration to elderly patients).

Precautions

This medication contains two key components used to control blood sugar. The first component inhibits the reabsorption of sugar in the kidneys, helping to lower blood sugar by allowing sugar to be excreted in urine. The second component helps in blood sugar control by inhibiting sugar production in the liver and improving insulin sensitivity. This medication should not be used in patients with renal impairment, dehydration, severe infections, cardiac disease, or during pregnancy and breastfeeding. Serious metabolic complications such as severe lactic acidosis can occur rarely; therefore, if symptoms such as malaise, muscular pain, breathlessness, or abdominal pain appear during use, immediate consultation with a physician is necessary. When taken with insulin or sulfonylureas, symptoms of hypoglycemia may occur, necessitating dosage adjustments. During use, urinary tract and genital infections may occur, so prompt treatment should be sought for any infection symptoms. Monitoring renal function regularly is crucial, as this medication may affect kidney function. Excessive alcohol consumption may increase the risk of side effects. It is advised to stop taking this medication for a certain period before and after surgery or radiographic contrast tests, and ensure renal function is normal before resuming. This medication may cause a decrease in fluid volume and blood pressure, necessitating careful observation for especially elderly patients or those on diuretics. Additionally, this medication may lower vitamin B12 levels; hence, checking vitamin B12 levels is recommended for long-term users. Dizziness may occur while driving or operating machinery, so caution is advised. Keep out of reach of children, and store it in its original container to maintain quality.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vulvitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • reduced fluid volume
  • thirst
Show 82 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • vitamin B12 deficiency
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burns
  • wrist fractures
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland masses
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremors
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • benign prostatic hyperplasia
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture, preferably at a temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Yellow oval-shaped extended-release film-coated tablet with both sides convex

Package unit

30 tablets/box [(10 tablets/PTP (Alu-Alu) x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.